search
Back to results

Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Cancer: a Multicenter Randomized Controlled Trial

Primary Purpose

Pancreas Neoplasm Malignant Resectable

Status
Recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Laparoscopic distal pancreatectomy
open distal pancreatectomy
Sponsored by
Seoul National University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreas Neoplasm Malignant Resectable focused on measuring pancreas neoplasms, pancreatectomy

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance score 0-2
  • Pancreatic ductal adenocarcinoma that is pathologically confirmed or shows characteristic radiologic features
  • Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy)
  • Lesion (within pancreatic body and tail) is located to the left of the left branch of the hepatic portal vein
  • No remote metastasis in preoperative imaging and not adjacent to the superior mesenteric vein, superior mesenteric artery, and abdominal artery
  • Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon
  • Patients with informed consent

Exclusion Criteria:

  • Patients with remote metastasis at the time of diagnosis of pancreatic cancer
  • History of other malignancy (Inclusive if there is no evidence of recurrence after 5 years of treatment)
  • In the case of invasion of other organs other than the left adrenal gland and mesocolon
  • Where major vascular resection, such as the portal vein or abdominal artery, is required to secure negative resection
  • Recurrent pancreatic cancer
  • Patients with underlying diseases at high risk of general anesthesia
  • Preperitoneal or other organ metastases found during surgery
  • In case of previously undergone pancreatic resection
  • Other subject whom the investigator deems inappropriate

Sites / Locations

  • Seoul National University Bundang HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Laparoscopic distal pancreatectomy

open distal pancreatectomy

Arm Description

Patients receiving laparoscopic distal pancreatectomy for pancreatic tail and body cancer

Patients receiving open distal pancreatectomy for pancreatic tail and body cancer

Outcomes

Primary Outcome Measures

2 year survival
Overall survival at 2 years after surgery

Secondary Outcome Measures

Full Information

First Posted
May 17, 2019
Last Updated
September 17, 2022
Sponsor
Seoul National University Hospital
Collaborators
Seoul National University Bundang Hospital, Severance Hospital, Asan Medical Center, Seoul St. Mary's Hospital, Samsung Medical Center, Gangnam Severance Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03957135
Brief Title
Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Cancer: a Multicenter Randomized Controlled Trial
Official Title
Multicenter Prospective Randomized Controlled Clinical Trial for Comparison Between Laparoscopic and Open Distal Pancreatectomy for Ductal Adenocarcinoma of the Pancreatic Body and Tail
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 20, 2019 (Actual)
Primary Completion Date
November 30, 2025 (Anticipated)
Study Completion Date
November 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
Collaborators
Seoul National University Bundang Hospital, Severance Hospital, Asan Medical Center, Seoul St. Mary's Hospital, Samsung Medical Center, Gangnam Severance Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
When pancreatic cancer of the body and tail is diagnosed, a distal pancreatectomy is planned. This operation can be performed with open surgery, or with laparoscopic surgery. This study is a multicenter randomized controlled trial to evaluate the operative outcomes and survival of open versus laparoscopic distal pancreatectomy for pancreatic cancer of the body and tail.
Detailed Description
* Purpose To compare the safety and oncologic feasibility of open versus laparoscopic distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma (PDAC) of the body and tail. * Study method Multicenter prospective randomized controlled trial Noninferiority analysis Patients diagnosed with PDAC of the body and tail, without evidence of distant metastasis or direct invasion of adjacent organs, will be randomly allocated to either the open distal pancreatectomy group or the laparoscopic distal pancreatectomy group. Postoperative outcomes and survival data will be analyzed. * Number of subjects Sample size was calculated based on 2 year survival after pancreatectomy. pA: 2 year survival of open distal pancreatectomy pB: 2 year survival of laparoscopic distal pancreatectomy Null hypothesis: The 2 year survival of laparoscopic distal pancreatectomy is inferior to that of open distal pancreatectomy. H0: pA-pB≥δ Alternative hypothesis: The 2 year survival of laparoscopic distal pancreatectomy is not inferior to that of open distal pancreatectomy. H1: pA-pB<δ 2 year survival of pancreatectomy (Shin et al, 2015) is 55.9% for open and 64.3% for laparoscopic distal pancreatectomy. When α=5%, 1-β=80%, δ=10%, and one-sided analysis is performed with a power of 80%, the required number of subjects is 111 for each group. With a drop rate of 10%, the final number of each group is 122, with a total of 244. * Primary and Secondary endpoints Primary endpoint: 2 year overall survival Secondary endpoint: R0 resection rate, 2 year disease free survival, 2 year recurrence rate, complication rate, postoperative hospital stay, operative time, estimated blood loss

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreas Neoplasm Malignant Resectable
Keywords
pancreas neoplasms, pancreatectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective randomized controlled clinical trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
244 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Laparoscopic distal pancreatectomy
Arm Type
Experimental
Arm Description
Patients receiving laparoscopic distal pancreatectomy for pancreatic tail and body cancer
Arm Title
open distal pancreatectomy
Arm Type
Active Comparator
Arm Description
Patients receiving open distal pancreatectomy for pancreatic tail and body cancer
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic distal pancreatectomy
Intervention Description
Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
Intervention Type
Procedure
Intervention Name(s)
open distal pancreatectomy
Intervention Description
Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
Primary Outcome Measure Information:
Title
2 year survival
Description
Overall survival at 2 years after surgery
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance score 0-2 Pancreatic ductal adenocarcinoma that is pathologically confirmed or shows characteristic radiologic features Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy) Lesion (within pancreatic body and tail) is located to the left of the left branch of the hepatic portal vein No remote metastasis in preoperative imaging and not adjacent to the superior mesenteric vein, superior mesenteric artery, and abdominal artery Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon Patients with informed consent Exclusion Criteria: Patients with remote metastasis at the time of diagnosis of pancreatic cancer History of other malignancy (Inclusive if there is no evidence of recurrence after 5 years of treatment) In the case of invasion of other organs other than the left adrenal gland and mesocolon Where major vascular resection, such as the portal vein or abdominal artery, is required to secure negative resection Recurrent pancreatic cancer Patients with underlying diseases at high risk of general anesthesia Preperitoneal or other organ metastases found during surgery In case of previously undergone pancreatic resection Other subject whom the investigator deems inappropriate
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jun Suh Lee, M.D. Ph.D.
Phone
+82-10-2747-6320
Email
rudestock@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yoo-Seok Yoon, M.D. Ph.D.
Email
arsyun@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ho-Seong Han, M.D. Ph.D.
Organizational Affiliation
Seoul National University Bundang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National University Bundang Hospital
City
Seongnam-si
State/Province
Kyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Suh Lee, M.D., Ph.D.
Phone
+82-10-2747-6320
Email
rudestock@gmail.com
First Name & Middle Initial & Last Name & Degree
Ho-Seong Han, M.D.,Ph.D.
First Name & Middle Initial & Last Name & Degree
Yoo-Seok Yoon, M.D.,Ph.D.

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25005018
Citation
Yoon YS, Lee KH, Han HS, Cho JY, Jang JY, Kim SW, Lee WJ, Kang CM, Park SJ, Han SS, Ahn YJ, Yu HC, Choi IS. Effects of laparoscopic versus open surgery on splenic vessel patency after spleen and splenic vessel-preserving distal pancreatectomy: a retrospective multicenter study. Surg Endosc. 2015 Mar;29(3):583-8. doi: 10.1007/s00464-014-3701-9. Epub 2014 Jul 9.
Results Reference
background
PubMed Identifier
19434700
Citation
Yoon YS, Lee KH, Han HS, Cho JY, Ahn KS. Patency of splenic vessels after laparoscopic spleen and splenic vessel-preserving distal pancreatectomy. Br J Surg. 2009 Jun;96(6):633-40. doi: 10.1002/bjs.6609.
Results Reference
background
PubMed Identifier
25529901
Citation
Shin SH, Kim SC, Song KB, Hwang DW, Lee JH, Lee D, Lee JW, Jun E, Park KM, Lee YJ. A comparative study of laparoscopic vs. open distal pancreatectomy for left-sided ductal adenocarcinoma: a propensity score-matched analysis. J Am Coll Surg. 2015 Feb;220(2):177-85. doi: 10.1016/j.jamcollsurg.2014.10.014. Epub 2014 Oct 31.
Results Reference
background

Learn more about this trial

Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Cancer: a Multicenter Randomized Controlled Trial

We'll reach out to this number within 24 hrs